Considering the particular condition of castration-resistant prostate cancer (defined as a PSA rise or a radiological progression in patients with castration levels of testosterone) [56], imaging assessment should include bone scintigraphy and TAP CECT (instead of PSMA PET/CT due to its limited diagnostic performance in this condition) [57]. This evidence concerns the gene FOLH1 and prostate cancer.